RJA
IART icon

Raymond James & Associates’s Integra LifeSciences IART Stock Holding History

Raymond James & Associates’s Portfolio IART Stock Details IART Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$868K Sell
47,750
-109,305
-70% -$2.53M ﹤0.01% 2775
2024
Q2 		$4.58M Sell
157,055
-71,544
-31% -$2.12M ﹤0.01% 1642
2024
Q1 		$8.1M Buy
228,599
+21,371
+10% +$855K 0.01% 1281
2023
Q4 		$9.02M Buy
207,228
+2,903
+1% +$114K 0.01% 1168
2023
Q3 		$7.8M Buy
204,325
+45,554
+29% +$1.92M 0.01% 1191
2023
Q2 		$6.53M Buy
158,771
+87,108
+122% +$4.19M 0.01% 1314
2023
Q1 		$4.11M Buy
71,663
+6,115
+9% +$345K ﹤0.01% 1598
2022
Q4 		$3.68M Buy
65,548
+22,151
+51% +$1.13M ﹤0.01% 1629
2022
Q3 		$1.84M Buy
43,397
+1,155
+3% +$59.2K ﹤0.01% 2025
2022
Q2 		$2.28M Buy
42,242
+1,785
+4% +$107K ﹤0.01% 1912
2022
Q1 		$2.6M Buy
40,457
+7,971
+25% +$525K ﹤0.01% 1943
2021
Q4 		$2.18M Sell
32,486
-88,022
-73% -$5.96M ﹤0.01% 2127
2021
Q3 		$8.25M Buy
120,508
+3,060
+3% +$216K 0.01% 1170
2021
Q2 		$8.02M Buy
117,448
+1,866
+2% +$132K 0.01% 1196
2021
Q1 		$7.99M Buy
115,582
+24,987
+28% +$1.69M 0.01% 1154
2020
Q4 		$5.88M Buy
90,595
+5,246
+6% +$282K 0.01% 1244
2020
Q3 		$4.03M Buy
85,349
+16,860
+25% +$802K 0.01% 1350
2020
Q2 		$3.22M Buy
68,489
+2,820
+4% +$139K ﹤0.01% 1447
2020
Q1 		$2.93M Sell
65,669
-3,410
-5% -$179K ﹤0.01% 1352
2019
Q4 		$4.03M Buy
69,079
+12,887
+23% +$767K 0.01% 1386
2019
Q3 		$3.38M Sell
56,192
-913
-2% -$54.4K ﹤0.01% 1473
2019
Q2 		$3.19M Buy
57,105
+415
+0.7% +$21.4K ﹤0.01% 1500
2019
Q1 		$3.16M Buy
56,690
+42
+0.1% +$2.14K ﹤0.01% 1474
2018
Q4 		$2.56M Buy
56,648
+3,412
+6% +$187K ﹤0.01% 1488
2018
Q3 		$3.51M Buy
53,236
+4,110
+8% +$255K 0.01% 1447
2018
Q2 		$3.16M Buy
49,126
+4,069
+9% +$252K 0.01% 1465
2018
Q1 		$2.49M Sell
45,057
-25,812
-36% -$1.35M ﹤0.01% 1578
2017
Q4 		$3.39M Sell
70,869
-1,335
-2% -$65.3K 0.01% 1352
2017
Q3 		$3.65M Buy
72,204
+19,612
+37% +$1.01M 0.01% 1256
2017
Q2 		$2.87M Buy
52,592
+2,311
+5% +$110K 0.01% 1350
2017
Q1 		$2.12M Buy
50,281
+2,099
+4% +$89.7K ﹤0.01% 1489
2016
Q4 		$2.07M Buy
48,182
+11,108
+30% +$452K 0.01% 1471
2016
Q3 		$1.53M Sell
37,074
-7,608
-17% -$319K ﹤0.01% 1622
2016
Q2 		$1.78M Sell
44,682
-1,350
-3% -$48.6K 0.01% 1397
2016
Q1 		$1.55M Buy
46,032
+722
+2% +$22.5K 0.01% 1435
2015
Q4 		$1.54M Sell
45,310
-1,928
-4% -$60.3K 0.01% 1402
2015
Q3 		$1.41M Sell
47,238
-24,170
-34% -$756K 0.01% 1415
2015
Q2 		$1.97M Buy
71,408
+17,598
+33% +$469K 0.01% 1327
2015
Q1 		$1.36M Sell
53,810
-6,606
-11% -$156K 0.01% 1473
2014
Q4 		$1.34M Buy
+60,416
New +$1.22M 0.01% 1390

Other funds holding IART

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SHCM
Sachem Head Capital Management New York $4.15B AUM 48.05% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Raymond James & Associates's IART Position: Q3 2024 in Review

Raymond James & Associates reduced its Integra LifeSciences (IART) stake by 70% in Q3 2024, selling an estimated $2.53M and leaving 47,750 shares worth $868K. The position accounts for ﹤0.01% of the portfolio, ranked #2775.

Raymond James & Associates first reported a position in IART in Q4 2014 and has held it in 40 quarters since. The position peaked at $9.02M in Q4 2023. 225 funds tracked by Wall St. Rank hold IART as of Q3 2024.

  • Raymond James & Associates held 47,750 shares of Integra LifeSciences worth $868K as of Q3 2024.
  • Raymond James & Associates sold 109,305 Integra LifeSciences shares in Q3 2024, an estimated $2.53M.
  • Integra LifeSciences made up ﹤0.01% of Raymond James & Associates's portfolio in Q3 2024, its #2775 holding.
  • Raymond James & Associates first reported a position in Integra LifeSciences in Q4 2014 and has held it in 40 quarters since.
  • Raymond James & Associates's Integra LifeSciences position peaked at $9.02M in Q4 2023.
  • 225 funds tracked by Wall St. Rank held Integra LifeSciences as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.